Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus Therapeutics to Present at 13th Annual LD Micro Main Event Conference
07:30am, Tuesday, 08'th Dec 2020
AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today ann
Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center
07:30am, Tuesday, 01'st Dec 2020
AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized the
Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma
08:00am, Thursday, 19'th Nov 2020
Investigational drug RNL ™ d eliver s u p to fifteen t imes the a bsorbed d ose of r adiation c ompared to standard e xternal b eam r adiation t herapy
Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update
07:30am, Friday, 13'th Nov 2020
Company Management and Principal Investigator of ReSPECT to Discuss Interim Data
Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial
07:00am, Thursday, 29'th Oct 2020
Data and Safety Monitoring Board evaluated safety data in recommending cohort progression Data and Safety Monitoring Board evaluated safety data in recommending cohort progression
